Bamco Inc. NY Makes New $3.54 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

Bamco Inc. NY bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the third quarter, Holdings Channel reports. The fund bought 31,000 shares of the company’s stock, valued at approximately $3,542,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Driehaus Capital Management LLC boosted its position in Vaxcyte by 3.6% during the second quarter. Driehaus Capital Management LLC now owns 1,934,747 shares of the company’s stock worth $146,093,000 after acquiring an additional 66,940 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Vaxcyte by 47.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock worth $148,075,000 after purchasing an additional 419,600 shares during the last quarter. Maverick Capital Ltd. grew its position in shares of Vaxcyte by 41.9% in the third quarter. Maverick Capital Ltd. now owns 976,249 shares of the company’s stock valued at $111,556,000 after purchasing an additional 288,341 shares in the last quarter. Novo Holdings A S increased its holdings in shares of Vaxcyte by 12.4% in the second quarter. Novo Holdings A S now owns 950,000 shares of the company’s stock valued at $71,734,000 after purchasing an additional 105,000 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in Vaxcyte by 14.3% during the second quarter. American Century Companies Inc. now owns 527,594 shares of the company’s stock worth $39,839,000 after buying an additional 65,870 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Activity at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 42,000 shares of Vaxcyte stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at $10,429,294.37. The trade was a 31.73 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Grant Pickering sold 7,098 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $109.21, for a total transaction of $775,172.58. Following the sale, the chief executive officer now directly owns 138,581 shares in the company, valued at $15,134,431.01. This represents a 4.87 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 110,464 shares of company stock worth $11,924,596. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Stock Performance

Vaxcyte stock opened at $90.37 on Wednesday. The company’s 50 day simple moving average is $104.69 and its 200-day simple moving average is $90.71. Vaxcyte, Inc. has a 1 year low of $52.74 and a 1 year high of $121.06. The company has a market capitalization of $11.26 billion, a price-to-earnings ratio of -19.65 and a beta of 0.94.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the previous year, the business posted ($0.91) earnings per share. Equities analysts expect that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PCVX has been the subject of several analyst reports. Leerink Partners upped their target price on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. Bank of America lifted their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. BTIG Research lifted their price target on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.